The Ramirez family cannot afford insulin
Maria works retail. Luis drives for a warehouse. Their son Diego needs daily insulin. Their marketplace plan lost enhanced subsidies.
What they get now
Rationing doses, crowdfunding, and ER visits when sugar crashes. Out-of-pocket insulin still spikes between refills.
What they should get
Negotiated insulin at near-cost, automatic coverage under Medicare for All / national drug negotiation, and no medical bankruptcy threat (Blueprint FIX-DRUG-001 and FIX-HC-001).
Best solution
Pass Medicare for All with national insulin negotiation (FIX-DRUG-001 + FIX-HC-001): one public payer sets near-cost insulin prices, covers Diego automatically, and bans rebate games that mark up a century-old medicine.
Why it works
Insulin is cheap to make. The U.S. price is a monopoly and coverage problem. One buyer plus automatic enrollment ends rationing faster than state coupon theater.
Why not the fair outcome?
Chain of responsibility
Follow the steps from power to lived harm. Each node names an actor, what they did, and what it caused - with receipts.
- 1CorporationsStep 1 of 6
Insulin list prices and rebate games stay far above manufacturing cost.
Effect: Families pay peer-leading U.S. prices even when the molecule is a century old.
Sources
- 2CongressStep 2 of 6
Drug-price negotiation stays narrow; broader Medicare negotiation bills stall.
Effect: Most commercial insulin stays outside the strongest federal bargaining tools.
Sources
- 3Trump adminStep 3 of 6
Enhanced ACA premium tax credits expire; marketplace premiums jump.
Effect: The Ramirez plan deductible rises and pharmacy benefits get thinner.
Sources
- 4State govStep 4 of 6
Medicaid work-requirement waivers add churn for low-wage workers who miss paperwork.
Effect: Coverage gaps appear exactly when refill day hits.
Sources
- 5PropagandaStep 5 of 6
Ads claim drug negotiation kills innovation and that insulin already is fixed.
Effect: Voters shrug while receipts show rationing and ER debt.
Sources
- 6Budget prioritiesStep 6 of 6
Federal capacity shifts toward enforcement and tax cuts for capital income, not pharmacy access.
Effect: Money that could buy insulin security buys detention beds and rebate theater instead.
Sources
Bottom line
Diego does not lack science. He lacks bargaining power, stable coverage, and a Congress that puts pharmacy prices above pharma talking points.